COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu
Trial record 1 of 1 for:    px-104
Previous Study | Return to List | Next Study

Safety Pilot Study of Farnesoid X Receptor (FXR) Agonist in Non-alcoholic Fatty Liver Disease (NAFLD) Patients

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01999101
Recruitment Status : Completed
First Posted : December 3, 2013
Last Update Posted : September 29, 2016
Medical University of Vienna
Information provided by (Responsible Party):
Phenex Pharmaceuticals AG

Brief Summary:
The primary aim of the study is to evaluate the safety and tolerability of Px-104 in NAFLD patients and to assess the influence of Px-104 on hepatic fat.

Condition or disease Intervention/treatment Phase
Non Alcoholic Fatty Liver Disease Drug: Px-104 Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 12 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Safety Pilot Study of Px-104 in Non-alcoholic Fatty Liver Disease (NAFLD) Patients
Study Start Date : October 2013
Actual Primary Completion Date : January 2015
Actual Study Completion Date : June 2016

Arm Intervention/treatment
Experimental: Px-104
Px-104 capsules, 5 mg
Drug: Px-104
28 days treatment

Primary Outcome Measures :
  1. Safety [ Time Frame: 28 days ]
    Analysis of clinical chemistry, hematology, and assessment of clinical signs and adverse events over 28 days. Change day 28 vs. day 1

Secondary Outcome Measures :
  1. Change of hepatocellular lipid content [ Time Frame: day 1 and day 28 ]
    Measurement of hepatic fat (%) by Magnetic resonance spectroscopy (MRS), change day 28 vs. day 1

  2. Changes in oral glucose tolerance test (oGTT) [ Time Frame: baseline and day 27 ]
    Measurement of plasma glucose level (mg/dL)

  3. Change from baseline in fibroblast growth factor 19 (FGF-19) [ Time Frame: days 1, 7, 14, 21 and 28 ]
    Measurement by ELISA (pg/mL)

  4. Change from baseline in plasma bile acid concentration [ Time Frame: days 1, 7, 14, 21, and 28. ]
    Assessment by LC-MS/MS (µmol/L)

  5. Pharmacokinetics of Px-104 and conjugates [ Time Frame: day 1 and day 28 ]
    Measurement by LC-MS/MS (ng/mL). AUC, Cmax and other pk parameters

Other Outcome Measures:
  1. Changes in the Saccharose-Lactulose-Mannitol + Sucralose (SLM+S) Test to evaluate the intestinal permeability [ Time Frame: baseline and day 27 ]
    Measurement of urinary concentrations of Saccharose, Lactulose, Mannitol and Sucralose by HPLC

  2. Assessment of liver steatosis by CAP-Fibroscan [ Time Frame: baseline and day 28 ]
    Measurement of hepatic fat (%) by CAP-Fibroscan

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 70 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • NAFLD patients
  • Weight > 65 kg
  • BMI > 25 and < 40
  • Negative blood or urine pregnancy test (for females of childbearing potential) collected at screening followed by another negative serum pregnancy test collected within 24 hours prior to the first dose of study drug.
  • Contraception: Female patients must be postmenopausal, surgically sterile, or if premenopausal, must be prepared to use at least two effective (≤1% failure rate) method of contraception during the course of the study and for 14 days after the end of dosing. Male patients with female partners of child bearing potential must be prepared to use at least two effective methods of contraception with all sexual partners unless they have had a prior vasectomy
  • Must be willing and able to give written informed consent and agree to comply with the study protocol.
  • Sinus rhythm in 12-lead ECG

Exclusion Criteria:

  • Evidence of excessive alcohol, drug or substance abuse (excluding marijuana use) within 1 year of first dose.
  • History or other evidence of a medical condition associated with chronic liver disease other than.
  • History or other evidence of decompensated liver disease (Child-Pugh Grade B or higher), coagulopathy, hyperbilirubinemia, hepatic encephalopathy, hypoalbuminemia, ascites, hepatic encephalopathy, and bleeding from esophageal varices are conditions consistent with decompensated liver disease.
  • Concomitant intake of fibrates or statins (at least 4-6 weeks before start; considering half life of medication).
  • Any clinically relevant findings in ECG (identified via 24h-Holter ECG or 12-Lead ECG) at screening
  • History of any structural cardiac disease.
  • In addition, patients with documented or presumed unstable coronary artery disease, stable or unstable cardiovascular disease or cerebrovascular disease.
  • One or more of the following conditions: (1) poorly controlled hypertension, OR (2) screening or baseline blood pressure ≥ 160 mmHg for systolic OR (3) screening or baseline blood pressure ≥ 100 mmHg for diastolic blood pressure.
  • Type I or II diabetes with HbA1C > 6.5% at screening and/or fasting plasma glucose > 7mmol/L (> 126 mg/dl).
  • History or other evidence of a clinically relevant ophthalmologic disorder due to diabetes mellitus or hypertension or history or other evidence of severe retinopathy (e.g., cytomegalovirus, macular degeneration).
  • Known sensibility to any ingredients contained in the investigational medicinal product (IMP)
  • All conditions that do not allow magentic resonance (MR) assessments
  • History of having received any investigational drug ≤ 3 months and/or 6 x half-life prior to the first dose of study drug or the expectation that such drugs will be used during the study. Patients enrolled in this study cannot be enrolled in another study for either research, diagnostic or treatment purposes.
  • Woman with childbearing potential unless using adequate contraception (see inclusion criteria); females who are pregnant or breast feeding.
  • History of severe allergic
  • Evidence of an active or suspected cancer, or a history of malignancy within the last 2 years, with the exception of patients with basal cell carcinoma that has been excised and cured.
  • History of any systemic anti-neoplastic or immunomodulatory treatment (including supraphysiologic doses of steroids and radiation) 6 months prior to the first dose of study drug or the expectation that such treatment will be needed at any time during the study.
  • History of bleeding disorders or anticoagulant use
  • History or other evidence of chronic pulmonary disease associated with functional limitation.
  • History of uncontrolled severe seizure disorder.
  • Poorly controlled thyroid dysfunction.
  • History of major organ transplantation with an existing functional graft.
  • Any signs of acute infection or inflammation
  • History or other evidence of severe illness, or any other conditions which would make the patient, in the opinion of the investigator, unsuitable for the study.
  • Any herbal supplements containing silymarin, tocopherol, vitamin C, riboflavins, proflavins, curcumin. (at least 4-6 months before the study)
  • Positive test at screening for anti-Hepatits A virus (HAV) Immunoglobulin M (IgM), Hebatitis B surface antigen (HBsAg), Anti-Hepatits B core Antigen Immunglobulin M antibody (anti-HBc IgM Ab), or anti-HIV Ab.
  • Subjects who have undergone surgery within the last 3 months.
  • Subjects who have had a prior gastrointestinal surgery.
  • Subjects who will be unavailable for the duration of the trial, who are unlikely to be compliant with the protocol, or who are felt to b unsuitable by the investigator for any other reason
  • Imprisonment

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01999101

Layout table for location information
Division of Gastroenterology and Hepatology, Department of Internal Medicine III
Vienna, Austria, 1090
Sponsors and Collaborators
Phenex Pharmaceuticals AG
Medical University of Vienna
Layout table for investigator information
Principal Investigator: Michael Trauner, Professor Dr med Medical University Vienna
Layout table for additonal information
Responsible Party: Phenex Pharmaceuticals AG Identifier: NCT01999101    
Other Study ID Numbers: PHS-Px-104-II-01
First Posted: December 3, 2013    Key Record Dates
Last Update Posted: September 29, 2016
Last Verified: November 2014
Additional relevant MeSH terms:
Layout table for MeSH terms
Liver Diseases
Fatty Liver
Non-alcoholic Fatty Liver Disease
Digestive System Diseases